ClinicalTrials.gg
RecruitingNCT07334366Updated Jan 13, 2026

Broccoli Sprout Extract for Cognitive Function

An interventional study of Broccoli sprout extract (BSE) and Placebo Control in Cognitive Dysfunction and Cognitive Decline, sponsored by Pusan National University Yangsan Hospital. Recruiting at 1 site in South Korea. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Pusan National University Yangsan Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2025, registered Dec 2025).
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of — 17 open to participants now, 24 under way, 5 of them phase 3. Cognitive Dysfunction · Korea, Republic of.

Planned enrollment
25th of 57
100 · median 94
Started
2025
with 12 others
No phase
37 of 74
8 open now
Primary completion
2026-12
later than 8 of 23 live
Registered
71st of 74
by date
Lead sponsor
5 of 74
Pusan National University Yangsan Hospital

Among the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 57 interventional ones that give a count, is one of 13 that started in 2025, is one of 37 with no phase, reaches primary completion later than 8 of the 23 other live ones, and was the 71st registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

17 of the 74 studies in Cognitive Dysfunction with a site in Korea, Republic of are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Cognitive Dysfunction with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This clinical trial aims to determine whether broccoli sprout extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.

The main questions are:

  • Does broccoli sprout extract improve cognitive function in participants?
  • What side effects occur when participants take broccoli sprout extract?
Read the detailed description

Researchers will compare broccoli sprout extract to a placebo to evaluate their effectiveness in improving cognitive function in participants.

Participants will:

  • Take dietary broccoli sprout extract or a placebo daily for 12 weeks.
  • Visit the clinic at screenig, 0, 6, and 12 weeks for checkups and tests
03

Conditions studied

  • Cognitive Dysfunction
  • Cognitive Decline

Keywords

  • cognition
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: Adults aged 55-85 years (inclusive), both male and female
  • Global Deterioration Scale (GDS) score of 2-3:

GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment

  • Absence of dementia according to established diagnostic criteria
  • Ability to read Korean

Exclusion criteria

Exclusion Criteria:

  • Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)
  • Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest)
  • Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients
  • Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism
  • Renal impairment: Serum creatinine ≥2 times the for the institution
  • Hepatic impairment: or ALT ≥2 times the upper limit of normal for the institution
  • Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress
  • Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities
  • Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period
  • Alcohol use disorder, severe
  • Food allergies: Known allergic reactions to study product components
  • Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Broccoli group

    This group takes broccoli sporout extract for 12 weeks.

    Dietary Supplement: Broccoli sprout extract (BSE)

  • Placebo comparator
    Placebo group

    This group takes placebo for 12 weeks.

    Dietary Supplement: Placebo Control

Interventions

  • Dietary supplementBroccoli sproutsStudies of Broccoli sproutsBroccoli sprouts pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    BSE 1,000 mg/day for 12 weeks

  • Dietary supplementPlacebo Control

    Placebo (crystalline cellulosel) 1,000 mg/day for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline to 12 weeks in total Computerized NeuroCognitive Function Test score comprising verbal learning test, digit span test, and auditory continuous performance test

    The change in total CNT score from baseline to 12 weeks, calculated as the sum of verbal learning test, digit span test, and auditory continuous performance test scores. Higher total CNT scores indicate better neurocognitive function across the domains of memory, attention, and sustained concentration. This composite measure assesses overall cognitive performance, where positive changes (increase in total score) indicate cognitive improvement and negative changes (decrease in total score) suggest cognitive decline.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline to 12 weeks in verbal learning test score

    The change in verbal learning test score from baseline to 12 weeks, measuring memory and learning capacity. Higher scores indicate better verbal memory and learning ability. This assessment evaluates the ability to acquire, retain, and recall verbal information over multiple learning trials. Positive changes (increase in score) indicate improvement\*\* in verbal memory function, while negative changes (decrease in score) suggest a decline in verbal learning capacity.

    Time frame: 12 weeks

  2. Change from baseline to 12 weeks in digit span test score

    The change in digit span test score from baseline to 12 weeks, measuring working memory and attention span. Higher scores indicate better working memory and attention capacity. This assessment evaluates the ability to temporarily hold and manipulate numerical information in memory through forward and backward digit recall tasks. Positive changes (increase in score) indicate improvement in working memory capacity, while negative changes (decrease in score) suggest decline in attention and short-term memory function.

    Time frame: 12 weeks

  3. Change from baseline to 12 weeks in auditory continuous performance test score

    The change in auditory continuous performance test score from baseline to 12 weeks, measuring sustained attention and concentration abilities. Higher scores indicate better sustained attention and concentration capacity. This assessment evaluates the capacity to maintain focused attention and respond appropriately to auditory stimuli over an extended period. Positive changes (increase in score) indicate improvement in sustained attention function, while negative changes (decrease in score) suggest decline in concentration and vigilance capabilities.

    Time frame: 12 weeks

  4. Change from baseline to 12 weeks in Korean Mini-Mental State Examination (MMSE-K) total score

    The change in MMSE-K total score from baseline to 12 weeks, providing a brief assessment of global cognitive function. Higher scores indicate better global cognitive function. This standardized instrument evaluates orientation, attention, memory, language, and visuospatial abilities. Positive changes (increase in score) indicate improvement in overall cognitive status, while negative changes (decrease in score) suggest decline in cognitive function.

    Time frame: 12 weeks

  5. Change from baseline to 12 weeks in serum brain-derived neurotrophic factor (BDNF) concentration

    The change in serum BDNF concentration from baseline to 12 weeks, measured in ng/mL or pg/mL. BDNF is a neurotrophin that plays a crucial role in neuronal survival, growth, and synaptic plasticity. Positive changes indicate increased BDNF levels associated with enhanced neuroplasticity and neuroprotection, while negative changes suggest decreased neurotrophic support.

    Time frame: 12 weeks

  6. Change from baseline to 12 weeks in serum malondialdehyde (MDA) concentration

    The change in serum MDA concentration from baseline to 12 weeks, measured in μmol/L or nmol/mL. MDA is a biomarker of lipid peroxidation and oxidative stress, reflecting cellular damage from reactive oxygen species. Positive changes indicate increased oxidative stress and cellular damage, while negative changes stress and improved antioxidant status.

    Time frame: 12 weeks

  7. Change from baseline to 12 weeks in serum superoxide dismutase (SOD) activity

    The change in serum SOD activity from baseline to 12 weeks, measured in U/mL or U/mg protein. SOD is a key antioxidant enzyme that catalyzes the dismutation of superoxide radicals, providing cellular protection against oxidative damage. Positive changes indicate enhanced antioxidant capacity and cellular protection, while negative changes suggest reduced antioxidant defense mechanisms.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 20 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 20 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 31, 2025
First posted
Jan 12, 2026
StartActual
Apr 16, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07334366
Responsible party
Sang Yeoup Lee (Professor, Pusan National University Yangsan Hospital) — Principal investigator
First posted
Jan 12, 2026
Start date
Apr 16, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 13, 2026

Study contacts

Sang Yeoup Lee, Professor, MD, PhD
Contact
drsaylee@gmail.com
360-2860 ext. 055
Ye Li Lee
Contact
yeri1230@gmail.com
360-2860 ext. 055

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Broccoli sprouts

Start the discussion